Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
February 26 2021 - 5:03PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE
13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For
the month of February 2021
Commission File Number: 001-38396
BIOFRONTERA
AG
(Registrant’s
name / Translation of registrant’s name into English)
Hemmelrather
Weg 201, D-51377 Leverkusen Germany
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F [X] Form:40-F [ ]
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): N/A
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): N/A
CONTENTS
On
February 23, 2021, Biofrontera AG (the “Company”) entered into an underwriting agreement (the “Underwriting
Agreement”) with The Benchmark Company, LLC (the “Representative”) and with the other underwriters
named therein for which the Representative is acting as representative, for a firm commitment public offering of 1,334,002
American Depositary Shares (“Offered ADSs”), each representing two ordinary shares of the Company at an offering price
of $6.68 per ADS. The Company received gross proceeds of approximately $8.9 million from the Offered ADSs sold, before deducting
underwriting discounts and commissions and expenses.
A
copy of the Underwriting Agreement is hereby attached as Exhibit 1.1 hereto, and the opinion of the Company’s German counsel
relating to the securities issued in this offering is hereby attached as Exhibit 5.1 hereto, both of which shall be deemed to
be incorporated by reference in the registration statement of Biofrontera AG on Form F-3 (No. 333-236021) (including any prospectuses
forming a part of such registration statement) and to be a part thereof from the date on which this report is filed to the extent
not superseded by documents or reports subsequently filed or furnished to the U.S. Securities and Exchange Commission.
EXHIBITS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
BIOFRONTERA
AG
|
|
|
|
|
By:
|
/s/ Hermann
Lübbert
|
|
Name:
|
Hermann
Lübbert
|
|
Title:
|
Chief
Executive Officer
|
|
|
|
|
By:
|
/s/
Thomas Schaffer
|
|
Name:
|
Thomas
Schaffer
|
|
Title:
|
Chief
Financial Officer
|
Date:
February 26, 2021
Biofrontera (NASDAQ:BFRA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biofrontera (NASDAQ:BFRA)
Historical Stock Chart
From Sep 2023 to Sep 2024